Injectables in the prostate

Saemi, Arash M; Plante, Mark

doi:10.1097/mou.0b013e3282f20169

Cited by 10 publications

(9 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intraprostatic injection therapy for BPH is an inexpensive and simple procedure, with various results reported since the early 1900s [62][63][64][65]. Many injectable agents have been explored, with most reported to induce coagulative necrosis, followed by shrinkage of the prostate and resulting improvements in voiding dysfunction.…”

Section: Injection Techniquesmentioning

confidence: 98%

Treating Benign Prostatic Hyperplasia with Botulinum Neurotoxin

Brisinda

Vanella²,

Marniga³

et al. 2011

CMC

View full text Add to dashboard Cite

Botulinum toxin (BoNT) has been increasingly used in the interventional treatment of several disorders; the use of this agent has extended to a plethora of conditions including focal dystonia, spasticity, inappropriate contraction in most gastrointestinal sphincters, eye movement disorders, hyperhidrosis, genitourinary disorders and aesthetically undesirable hyperfunctional facial lines. In addition, BoNT is being investigated for the control of pain, and for the management of tension or migraine headaches and myofascial pain syndrome. Benign prostatic hyperplasia (BPH) is a common condition in ageing men; the goal of therapy is to reduce the lower urinary tract symptoms (LUTS) associated with BPH and to improve the quality of life. However, medical treatment, including drugs that relax smooth muscle within the prostate and drugs that shrink the gland are not totally effective or without complications. The standard surgical treatment for BPH is progressively changing to minimally invasive therapies, but none of them has provided clear results. The use of BoNT-A to inhibit the autonomic efferent effects on prostate growth and contraction, and inhibit the abnormal afferent effects on prostate sensation, might be an alternative treatment for BPH. BoNT injections have several advantages over drugs and surgical therapies in the management of intractable or chronic disease; systemic pharmacologic effects are rare, permanent destruction of tissue does not occur, and graded degrees of relaxation may be achieved by varying the dose injected. In this paper, clinical experience over the last years with BoNT in BPH impaired patients will be illustrated.

show abstract

Section: Injection Techniquesmentioning

confidence: 98%

Treating Benign Prostatic Hyperplasia with Botulinum Neurotoxin

Brisinda

Vanella²,

Marniga³

et al. 2011

CMC

View full text Add to dashboard Cite

show abstract

“…8 The key goals in the management of BPH are represented by controlling symptoms, preventing complications, and improving QoL. 9 While TURP still represents the gold standard treatment for BPH and despite many technical advances, the morbidity of this procedure has remained constant, in the range of 15% to 18%, with fluid absorption with dilutional hyponatremia and TUR syndrome, glycine toxicity, perforation, erectile dysfunction, retrograde ejaculation, and blood loss being the main areas of concern.…”

Section: Discussionmentioning

confidence: 99%

Transurethral Ethanol Ablation of the Prostate for Symptomatic Benign Prostatic Hyperplasia: Long-Term Follow-Up

El‐Husseiny

Buchholz²

2011

Journal of Endourology

View full text Add to dashboard Cite

show abstract

“…33 With the advent of novel injectables, this approach has experienced renewed interest. 34,35 The obvious advantages of a truly minimally invasive procedure include the absence of the adverse events associated with medical treatment, the lack of compliance issues that occur with long-term oral medication, the lack of an urgent need for anaesthesia and the minimal risk of technical adverse effects and complications. In times of dramatically rising health-care costs in an aging population, economic aspects are of critical importance and a cost-effective, easy-to-perform and efficient therapy performed in an office-based setting is desirable.…”

Section: Intraprostatic Injectionmentioning

confidence: 99%

New intraprostatic injectables and prostatic urethral lift for male LUTS

2015

View full text Add to dashboard Cite

Treatment modalities for male lower urinary tract symptoms (LUTS) comprise a broad spectrum of medical and surgical options. Interest is growing in minimally invasive treatment options, which should ideally be performed in an outpatient setting and have a short recovery time, durable efficacy and a good safety profile. The preservation of all aspects of sexual function, including antegrade ejaculation, seems to be increasingly important for patients. Initial experimental data on new minimally invasive procedures-such as the intraprostatic injection of novel agents including botulinum neurotoxin A (BoNT-A), NX-1207 and PRX302-were promising, but clinical trials have not confirmed the findings. Trials of the mechanical prostatic urethral lift device-Urolift(®) (Neotract, Inc., USA)-have been positive, but further long-term results are needed to confirm its beneficial effects.

show abstract

Injectables in the prostate

Cited by 10 publications

References 29 publications

Treating Benign Prostatic Hyperplasia with Botulinum Neurotoxin

Treating Benign Prostatic Hyperplasia with Botulinum Neurotoxin

Transurethral Ethanol Ablation of the Prostate for Symptomatic Benign Prostatic Hyperplasia: Long-Term Follow-Up

New intraprostatic injectables and prostatic urethral lift for male LUTS

Contact Info

Product

Resources

About